The document reviews biologic therapies for severe asthma. It provides a case summary of a patient with severe eosinophilic asthma. It then outlines the educational aims, definitions, pathophysiology, and classes of biologic therapies. For each biologic class, it summarizes key trials showing reductions in exacerbation rates. It identifies predictors of response and side effects. The take home messages are that all biologics effectively reduce exacerbations, anti-IL5 therapies are superior for patients on oral corticosteroids, and drug availability and other indications should be considered when choosing therapy.
Bronchial Asthma- Recent advances in management by Dr. Jebin AbrahamJebin Abraham
Bronchial asthma, Asthma phenotypes, newer bronchodilators, personalised medicine in asthma, pharmacogenetics of current drugs, immunotherapy, vaccination, bronchial thermoplasty, surgical management
Bronchial Asthma- Recent advances in management by Dr. Jebin AbrahamJebin Abraham
Bronchial asthma, Asthma phenotypes, newer bronchodilators, personalised medicine in asthma, pharmacogenetics of current drugs, immunotherapy, vaccination, bronchial thermoplasty, surgical management
Bronchial Thermoplasty (BT) Novel Treatment for Patients with Severe AsthmaBassel Ericsoussi, MD
Do our Asthma Patients Know What They Are Missing?Now, A Revolutionary Procedure Can Help Them Lead A Fuller Life.
Bronchial Thermoplasty (BT) Novel Treatment For Patients With Severe Asthma
Bronchial Thermoplasty (BT) Novel Treatment for Patients with Severe AsthmaBassel Ericsoussi, MD
Do our Asthma Patients Know What They Are Missing?Now, A Revolutionary Procedure Can Help Them Lead A Fuller Life.
Bronchial Thermoplasty (BT) Novel Treatment For Patients With Severe Asthma
Jonathan Corren, MD, and Paul Yamauchi, MD, prepared useful Practice Aids pertaining to allergic and inflammatory diseases for this CME/MOC/CNE/CPE activity titled "Advances in the Management of Allergic and Inflammatory Diseases: Highlights From Washington, DC and San Francisco." For the full presentation, monograph, complete CME/MOC/CNE/CPE information, and to apply for credit, please visit us at http://bit.ly/2OQpC1n. CME/MOC/CNE/CPE credit will be available until April 11, 2020.
The primary aims of COPD drug research are to develop agents capable of either inhibiting COPD-mediating inflammatory cell recruitment and activation directly, or indirectly - by targeting inflammatory mediators and blocking them from interacting with inflammatory cells.
As neutrophilic inflammation is present in most COPD cases, so first attempts at developing biologics for COPD therapy have focused on targeting the mechanisms of T1 inflammation.
Attempts at safe and effective mAb-mediated CXCR2 inhibition and TNF-a inhibition have also been unsuccessful, with high incidence of adverse effects and no improvements in patient health found in clinical trials.
Thus, further attempts at COPD biologics have turned their attention to primarily treating COPD related eosinophilia.
Emma Guttman-Yassky, MD, PhD, and Weily Soong, MD, prepared useful Practice Aids pertaining to atopic dermatitis, asthma, nasal polyposis, and eosinophilic esophagitis for this CME/MOC activity titled "New Developments in Allergic and Inflammatory Diseases: Clinical Updates From San Diego and Orlando." For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at http://bit.ly/2pZa5Rx. CME/MOC credit will be available until April 16, 2019.
Asthma is the most frequent chronic illness in children and is a common noncommunicable disease (NCD) that affects both adults and children. Coughing, wheezing, chest tightness, and shortness of breath are among the symptoms. This presentation target therapies for Asthma including its clinical use, etc. For more information, please contact us: 9779030507.
Synthetic Fiber Construction in lab .pptxPavel ( NSTU)
Synthetic fiber production is a fascinating and complex field that blends chemistry, engineering, and environmental science. By understanding these aspects, students can gain a comprehensive view of synthetic fiber production, its impact on society and the environment, and the potential for future innovations. Synthetic fibers play a crucial role in modern society, impacting various aspects of daily life, industry, and the environment. ynthetic fibers are integral to modern life, offering a range of benefits from cost-effectiveness and versatility to innovative applications and performance characteristics. While they pose environmental challenges, ongoing research and development aim to create more sustainable and eco-friendly alternatives. Understanding the importance of synthetic fibers helps in appreciating their role in the economy, industry, and daily life, while also emphasizing the need for sustainable practices and innovation.
Macroeconomics- Movie Location
This will be used as part of your Personal Professional Portfolio once graded.
Objective:
Prepare a presentation or a paper using research, basic comparative analysis, data organization and application of economic information. You will make an informed assessment of an economic climate outside of the United States to accomplish an entertainment industry objective.
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
How to Make a Field invisible in Odoo 17Celine George
It is possible to hide or invisible some fields in odoo. Commonly using “invisible” attribute in the field definition to invisible the fields. This slide will show how to make a field invisible in odoo 17.
Normal Labour/ Stages of Labour/ Mechanism of LabourWasim Ak
Normal labor is also termed spontaneous labor, defined as the natural physiological process through which the fetus, placenta, and membranes are expelled from the uterus through the birth canal at term (37 to 42 weeks
Operation “Blue Star” is the only event in the history of Independent India where the state went into war with its own people. Even after about 40 years it is not clear if it was culmination of states anger over people of the region, a political game of power or start of dictatorial chapter in the democratic setup.
The people of Punjab felt alienated from main stream due to denial of their just demands during a long democratic struggle since independence. As it happen all over the word, it led to militant struggle with great loss of lives of military, police and civilian personnel. Killing of Indira Gandhi and massacre of innocent Sikhs in Delhi and other India cities was also associated with this movement.
3. Case summary:
Young female lady with severe
eosinophilic asthma with frequent
relapses, on high dose ICS, LABA and
LAMA.
No obvious exacerbating factors.
Recurrent use of systemic steroids
complicated by HTN, Pre-diabetes
and osteopenia.
4. Educational aims:
To review the major outcome data
from phase 3 and real-world studies of
biologic therapies for severe asthma.
To understand the key baseline
characteristics associated with
response to each biologic therapy.
To gain awareness of the practical
issues that can impact the choice of
biologic therapies in asthma
9. Biologics classes
Class Name Age* Asthma indication* Other indications*
Anti-IgE Omalizumab (SC) ≥6 years Severe allergic asthma Nasal polyposis, chronic
spontaneous urticaria
Anti-IL5
Anti-IL5R
Mepolizumab (SC)
Reslizumab (IV)
Benralizumab (SC)
≥6 years
≥18 years
≥12 years
Severe eosinophilic/Type 2
asthma
Mepolizumab: EGPA,
CRSwNP,
hypereosinophilic
syndrome
Anti-IL4R Dupilumab (SC) ≥6 years Severe eosinophilic/Type 2
asthma, or maintenance
OCS
Moderate-severe atopic
dermatitis, CRSwNP
Anti-TSLP Tezepelumab (SC) ≥12 years Severe asthma
10. Severe asthma phenotypes (5-
10%):
Type 2/eosinophilic asthma: 70%
Fraction of exhaled nitric oxide
Neutrophilic asthma
11. Methods: Bronchial biopsies from 3 groups
(N 20 each group):
Subjects with mild steroid-naïve asthma, with either low
or high submucosal eosinophil counts .
Healthy controls.
Assessed for in vivo epithelial damage (using EGFR
staining), mucin expression, airway smooth muscle (ASM)
hypertrophy and inflammatory cells within ASM.
18. At ages 21, 26, 32 and 38 years,
blood was drawn at the end of the
assessment day.
Spirometry was performed at ages 18,
21, 26, 32 and 38 years.
20. Omalizumab
Systematic review of 25 trials were
included.
Inclusion criteria on patients who had
evidence of sensitisation to
aeroallergens, airway
hyperresponsiveness and ongoing
asthma symptoms.
21. Selection criteria: Randomised
controlled trials.
Two review authors independently
assessed study quality and extracted
and entered data.
22. Results:
25% reduction in exacerbation rate
over 16 to 60 weeks
Reduction in ICS.
No effect on mOCS reduction.
23. Predictors of response
Participants who had required emergency
asthma treatment.
On high dose ICS.
Lower FEV1 at baseline.
Neither allergen-specific IgE nor total IgE
predicts response to treatment.
Elevated T2 biomarkers at the time of
omalizumab cessation was shown to be a
predictor of future exacerbation
24. Mode of administration:
SC injection every 2-4 weeks.
frequency determined by weight and
serum IgE.
S.E:
Injection site reaction.
Arthralgia.
Dizziness.
25. Mepolizumab MENSA trial
Methods: In this randomized, double-blind, we assigned 576
patients with recurrent asthma exacerbations and evidence
of eosinophilic inflammation despite high doses of inhaled
glucocorticoids to one of three study groups.
Inclusion criteria included an eosinophilic phenotype (with
blood eosinophils of ≥150 cells・μL−1 at screening, or ≥300
cells・μL−1 in the past 12 months) and frequent
exacerbations
26. Patients were assigned to receive
mepolizumab, which was
administered as either a 75-mg
intravenous dose or a 100-mg
subcutaneous dose, or placebo every
4 weeks for 32 weeks
27. Results:
Rate of exacerbations was reduced by
47% in patients receiving IV
mepolizumab and by 53% in those
receiving SC mepolizumab, as
compared with those receiving
placebo.
ER visits reduced by 32% in IV
mepolizumab and by 61% in SC one.
29. Results:
At 24 weeks,14% of subjects treated
with mepolizumab were able to
completely stop prednisolone and
overall, a median reduction of 50%
was achieved.
30. Predictors of response:
In those with high blood eosinophils of
≥500 cells・μL−1 there was a 79%
reduction in exacerbation rate versus
placebo.
31. Length of treatment:
Open label extension study
(“COLUMBIA”) has confirmed a
sustained response to mepolizumab
up to 4.5 years of treatment
33. Reslizumab
Two phase 3 trials.
Enrolled patients with asthma aged
12-75 years (from 128 clinical
research centres in study 1 and 104
centres in study 2).
34. Results:
50–59% reduction in annual
exacerbation rate.
Improvement in FEV1.
Despite very good efficacy in severe
eosinophilic asthma, the need to give
reslizumab intravenously is a major
practical consideration
35. Benralizumab
Primary outcomes: Two large phase
3 trials in severe eosinophilic asthma
(SIROCCO and CALIMA).
In those with blood eosinophils <300
cells・μL−1, there was a 17–40%
reduction in exacerbation rate
compared with placebo, compared to
a 28–51% reduction in those with
eosinophils ≥300 cells・μL
36. The ZONDA study enrolled OCS-
dependent patients and demonstrated
a 50% reduction in OCS dose
compared with placebo.
37. Predictors of response
High baseline exacerbation rate
Higher blood eosinophils.
Nasal polyposis.
Low baseline forced vital capacity
(FVC) (< 65%).
Dependence on OCS.
38. Duration of therapy:
MELTEMI study has provided
evidence of continued efficacy along
with reassuring safety data out to 5
years.
39. Given at fixed dose SC injection,
every 4 weeks for 1st three doses,
then every 8 weeks.
A.E:
◦ Injection site reactions (2–3%).
◦ Nasopharyngitis
40. Tezepelumab:
Primary outcomes: “NAVIGATOR”
study.
Overall, treatment with tezepelumab
led to a reduction in exacerbation rate
of 56% versus placebo
42. Comparative effectiveness of Anti-IL5 and
Anti-IgE biologic classes in severe asthma
patients eligible for both:
Prospective cohort study.
22 countries.
long-term-oral corticosteroid (LTOCS) use.
Asthma-related emergency room (ER) attendance.
Hospital admissions.
43.
44.
45.
46.
47. Take home messages:
All biologics are effective in terms of
number exacerbations reduction.
In patient on mOCS, anti-IL5 are
superior.
Presence of other indications.
Availability of drugs.
Based on currently available data, for
most patients with severe eosinophilic
asthma the majority of these therapies
are likely to be effective.
48. Refferences:
Normansell R, Walker S, Milan SJ, et al. Omalizumab for
asthma in adults and children. Cochrane Database Syst Rev
2014; 1: CD003559.
Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment
in patients with severe eosinophilic asthma. N Engl J Med.
Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and
safety of benralizumab for patients with severe asthma
uncontrolled with high-dosage inhaled corticosteroids and
long-acting β2-agonists (SIROCCO): a randomised,
multicentre, placebo-controlled phase 3 trial. Lancet 2016;
FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an
anti-interleukin-5 receptor α monoclonal antibody, as add-on
treatment for patients with severe, uncontrolled, eosinophilic
asthma (CALIMA): a randomised, double-blind, placebo
controlled phase 3 trial. Lancet 2016;
Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment
in patients with severe eosinophilic asthma. N Engl J Med.